Header Logo

Connection

Leslie Shaw to Cyclosporine

This is a "connection" page, showing publications Leslie Shaw has written about Cyclosporine.
Connection Strength

1.212
  1. McKaig SJ, Kelly D, Shaw L. Investigation of the effect of FK506 (tacrolimus) and cyclosporin on gingival overgrowth following paediatric liver transplantation. Int J Paediatr Dent. 2002 Nov; 12(6):398-403.
    View in: PubMed
    Score: 0.197
  2. Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem. 2000 Jun; 46(6 Pt 1):872-4.
    View in: PubMed
    Score: 0.167
  3. Oellerich M, Armstrong VW, Sch?tz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem. 1998 Jul; 31(5):309-16.
    View in: PubMed
    Score: 0.146
  4. Shaw LM, Annesley T, Gilmore B, Brayman K. Measurement of OG37-325 by high-performance liquid chromatography. Transplant Proc. 1994 Oct; 26(5):3010-2.
    View in: PubMed
    Score: 0.113
  5. Roby KA, Shaw LM. Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol. 1993 Aug; 4(2):168-77.
    View in: PubMed
    Score: 0.104
  6. Yatscoff RW, Shaw LM. Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. Ther Drug Monit. 1992 Aug; 14(4):267-8.
    View in: PubMed
    Score: 0.097
  7. Terrell AR, Daly TM, Hock KG, Kilgore DC, Wei TQ, Hernandez S, Weibe D, Fields L, Shaw LM, Scott MG. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer. Clin Chem. 2002 Jul; 48(7):1059-65.
    View in: PubMed
    Score: 0.048
  8. Hosey MT, Davison SM, Gordon G, Shaw L, Kelly DA. Cytomegalovirus and cyclosporin-induced gingival overgrowth in children with liver grafts. Int J Paediatr Dent. 2002 Jul; 12(4):236-43.
    View in: PubMed
    Score: 0.048
  9. Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999 Oct; 21(10):1632-52; discussion 1631.
    View in: PubMed
    Score: 0.040
  10. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
    View in: PubMed
    Score: 0.035
  11. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996 Aug; 42(8 Pt 2):1316-21.
    View in: PubMed
    Score: 0.032
  12. Heifets M, Cooney GF, Shaw LM, Libetti G. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplantation. 1995 Dec 27; 60(12):1615-7.
    View in: PubMed
    Score: 0.031
  13. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995 Dec; 17(6):642-54.
    View in: PubMed
    Score: 0.031
  14. Hosey MT, Gordon G, Kelly DA, Shaw L. Oral findings in children with liver transplants. Int J Paediatr Dent. 1995 Mar; 5(1):29-34.
    View in: PubMed
    Score: 0.029
  15. Cooney GF, Heifets M, Bell A, Shaw LM, LiBetti G. Utility of pretransplantation cyclosporine pharmacokinetic studies. Ther Drug Monit. 1994 Apr; 16(2):151-4.
    View in: PubMed
    Score: 0.027
  16. de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009 Dec; 36(6):541-64.
    View in: PubMed
    Score: 0.020
  17. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
    View in: PubMed
    Score: 0.019
  18. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002 Feb; 24(1):59-67.
    View in: PubMed
    Score: 0.012
  19. Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. Transplant Proc. 1997 Dec; 29(8):3669-70.
    View in: PubMed
    Score: 0.009
  20. Weber M, Ketchum RJ, Sellers M, Aradhye S, Deng S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. Transplant Proc. 1997 Feb-Mar; 29(1-2):338-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.